Skip to main content
HitGen Inc. logo

HitGen Inc. — Investor Relations & Filings

Ticker · 688222 ISIN · CNE1000040G3 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 629 across all filing types
Latest filing 2023-04-28 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688222

About HitGen Inc.

https://www.hitgen.com/en

HitGen Inc. is a technology-driven research and development organization focused on the discovery of novel small molecule drug candidates. The company leverages its proprietary DNA-encoded library (DEL) platform, which features a collection of over 1.2 trillion diverse small molecules, to enable efficient hit identification and lead optimization. HitGen offers integrated drug discovery services, incorporating fragment-based drug discovery (FBDD) and structure-based drug design through its specialized research facilities. Its core operations include collaborative research partnerships with global pharmaceutical entities and the development of an internal pipeline of therapeutic programs. The platform combines synthetic chemistry, biology, and data informatics to streamline the identification of bioactive compounds for complex therapeutic targets.

Recent filings

Filing Released Lang Actions
成都先导药物开发股份有限公司关于聘任财务负责人的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the appointment of a new financial officer (Chief Financial Officer) at the company 成都先导药物开发股份有限公司. It details the board meeting decision, the new appointee's qualifications, and the departure of the previous financial officer from that role. There is no financial data, no report attached or referenced as being published, and no mention of regulatory filings or certifications. This fits the category of Board/Management Information (MANG), which covers announcements of changes in senior management.
2023-04-28 Chinese
成都先导药物开发股份有限公司2023年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2023 年第一季度报告' which translates to '2023 First Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the first quarter of 2023. The report is unaudited as indicated. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year clearly identifies this as an Interim / Quarterly Report. The document length is over 10,000 characters and contains substantive financial data, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2023
2023-04-28 Chinese
成都先导药物开发股份有限公司董事会审计委员会2022年度履职报告
Audit Report / Information Classification · 95% confidence The document is titled as the "Board of Directors Audit Committee 2022 Annual Performance Report" of Chengdu Lead Drug Development Co., Ltd. It details the activities, meetings, and evaluations conducted by the audit committee during the 2022 fiscal year. The content focuses on the audit committee's supervision of external auditors, internal audit guidance, review of financial reports, internal control guidance, and coordination between management and auditors. It is a report on the audit committee's duties and performance rather than a full audit report or annual report. The document length is 2701 characters, which is relatively short and focused on committee activities rather than comprehensive financial statements or audit opinions. This fits the category of an Audit Report / Information (AR) as it is a standalone report related to audit committee activities and audit supervision, not the full annual report or financial statements themselves. FY 2022
2023-04-28 Chinese
成都先导药物开发股份有限公司独立董事关于第二届董事会第九次会议相关事项的事前认可意见
Regulatory Filings
2023-04-28 Chinese
成都先导药物开发股份有限公司2022年年度报告摘要
Annual Report Classification · 100% confidence The document is titled "2022 年年度报告摘要" which translates to "2022 Annual Report Summary". It contains detailed financial data for the year 2022, including revenue, net profit, cash flow, and other key financial indicators. It also discusses the company's business model, industry position, risk factors, and future outlook. The length of the document (over 14,000 characters) and the presence of substantive financial data and management discussion indicate this is a full annual report rather than a brief announcement or summary. There is no indication that this is merely an announcement of a report or a certification. Therefore, the document fits the definition of an Annual Report (10-K). FY 2022
2023-04-28 Chinese
关于成都先导药物开发股份有限公司非经营性资金占用及其他关联资金往来情况汇总表的专项审计报告
Audit Report / Information Classification · 95% confidence The document is titled as a "专项审计报告" (special audit report) concerning non-operating fund occupation and other related party fund transactions for Chengdu Lead Drug Development Co., Ltd. It is prepared by Deloitte Huayong CPA firm. The content includes detailed tables of fund occupation and related party transactions for the year ending December 31, 2022. This indicates it is a standalone audit report focusing on specific audit matters rather than a full annual report or interim report. The document length is 1725 characters, which is relatively short but contains substantive audit findings and data, not just an announcement or certification. Therefore, it fits the category of Audit Report / Information (AR). FY 2022
2023-04-28 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.